A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

PURPOSE: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [(177)Lu]Lu-satoreotide tetraxetan in 40 patients with previously treated, progressive neuroendocrine tumours (NETs), in which dosimetry was used...

Descripción completa

Detalles Bibliográficos
Autores principales: Wild, Damian, Grønbæk, Henning, Navalkissoor, Shaunak, Haug, Alexander, Nicolas, Guillaume P., Pais, Ben, Ansquer, Catherine, Beauregard, Jean-Mathieu, McEwan, Alexander, Lassmann, Michael, Pennestri, Daniele, Volteau, Magali, Lenzo, Nat P., Hicks, Rodney J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684626/
https://www.ncbi.nlm.nih.gov/pubmed/37721581
http://dx.doi.org/10.1007/s00259-023-06383-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684626/
https://www.ncbi.nlm.nih.gov/pubmed/37721581
http://dx.doi.org/10.1007/s00259-023-06383-1

Ejemplares similares